Angiotensin converting enzyme inhibitors (ACEI) were first introduced in 1981. They are widely used in the field of hypertension, heart failure and kidney dysfunction. In general, ACEI are effective in a high percentage of patients and are well tolerated. However, cough might sometimes appear. The cough is typically dry and is associated with a tickling or scratching sensation in the throat [1]. ACEI-induced cough is not dose-dependant [2]. In a metanalysis of clinical trials, Bangalore et al. showed that ACEI cough appears in 11.48% of cases and authors suggested that ACEI-induced cough was generally underestimated [3].